NanoViricides, Inc. (NNVC) Cash Flow Statement
Where NNVC’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$7.70T
- Capital expenditures
- $84.32B
- Free cash flow
- −$7.78T
- Returned to shareholders
- —
- Change in cash
- $1.24T cash at year-end $2.79T
Drawn to scale: where the cash came from and how it was used. Hover for values.
NNVC operating cash flow, capex and free cash flow
NNVC cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$7.9MFY2017 | −$7.70TFY2026 | — | |
| Capital expenditures | $164,978FY2017 | $84.32BFY2026 | +330.8%/yr | |
| Free cash flow | −$8.1MFY2017 | −$7.78TFY2026 | — | |
| Stock-based compensation | $1.6MFY2017 | $49.62BFY2026 | +215.5%/yr | |
| Dividends paid | $0FY2017 | $0FY2018 | — | |
| Share buybacks (net) | $0FY2017 | $0FY2020 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NNVC cash flow by activity
NNVC net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
NNVC cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$8.22T | −$9.5M | −$8.3M | −$8.6M | −$8.1M | −$8.8M | −$13.4M | −$8.4M | −$8.6M | −$10.3M |
| Depreciation & amortization | $525,286 | $743,805 | $759,014 | $747,529 | $723,325 | $704,538 | $699,724 | $695,911 | $680,058 | $662,954 |
| Stock-based compensation | $49.62B | $223,347 | $222,185 | $214,179 | $338,418 | $405,594 | $559,398 | $532,320 | $791,164 | $1.6M |
| Change in working capital | −$371,000 | $20,456 | $996,877 | $1.8M | $214,563 | −$540,112 | $119,664 | $567,709 | $32,380 | −$485,858 |
| Other non-cash items | $472.87B | $679 | $563 | $157,999 | $939,303 | $38,332 | $5.4M | −$174,270 | −$716,015 | $629,080 |
| Cash from operating activities | −$7.70T | −$8.5M | −$6.3M | −$5.7M | −$5.9M | −$8.2M | −$6.7M | −$6.8M | −$7.8M | −$7.9M |
| Investing activities | ||||||||||
| Capital expenditures | −$84.32B | −$56,964 | −$156,560 | −$151,712 | −$324,348 | −$238,764 | −$8,638 | −$73,794 | −$241,822 | −$164,978 |
| Investments (net) | — | −$56,964 | −$156,560 | −$151,712 | −$324,348 | −$238,764 | −$8,638 | −$73,794 | −$241,822 | −$164,978 |
| Acquisitions & other investing | $0 | $56,964 | $156,560 | $151,712 | $324,348 | $238,764 | $8,638 | $73,794 | $241,822 | $164,978 |
| Cash from investing activities | −$84.32B | −$56,964 | −$156,560 | −$151,712 | −$324,348 | −$238,764 | −$8,638 | −$73,794 | −$241,822 | −$164,978 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share repurchases & issuance (net) | — | — | — | — | — | — | $16.7M | $2.4M | $0 | $0 |
| Net borrowing (repayment) | — | — | $0 | −$94,788 | −$234,716 | −$1.3M | $1.1M | $1.2M | $1.2M | −$1.0M |
| Shares issued | $0 | $5.3M | $3.1M | $0 | $6.1M | $16.6M | $16.7M | $2.4M | $0 | $0 |
| Other financing | $9.02T | $0 | $0 | $0 | −$6.1M | $0 | −$16.6M | −$3.5M | $3.4M | $0 |
| Cash from financing activities | $9.02T | $5.3M | $3.1M | −$94,788 | −$234,716 | $15.3M | $17.8M | $2.4M | $4.6M | −$1.0M |
| Summary | ||||||||||
| Net change in cash | $1.24T | −$3.2M | −$3.4M | −$5.9M | −$6.5M | $6.8M | $11.2M | −$4.5M | −$8.0M | −$9.1M |
| Cash at end of period | $2.79T | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M |
| Free cash flow | −$7.78T | −$8.5M | −$6.5M | −$5.8M | −$6.2M | −$8.5M | −$6.7M | −$6.9M | −$8.0M | −$8.1M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$438.34B | −$2.0M | −$2.2M | −$1.8M | −$2.1M | −$2.2M | −$2.0M | −$3.1M | −$2.4M | −$1.9M | −$2.1M | −$2.0M |
| Depreciation & amortization | $129,749 | $129,634 | $133,083 | $132,820 | $161,126 | $191,183 | $195,883 | $195,613 | $190,603 | $189,956 | $189,331 | $189,124 |
| Stock-based compensation | −$125.0M | $71,127 | $196,684 | $49,882 | $52,183 | −$65,853 | $52,255 | $60,158 | −$130,609 | $54,779 | $47,608 | $71,467 |
| Change in working capital | −$78,187 | −$142,098 | −$158,828 | $8,366 | $180,531 | −$24,277 | −$411,746 | $275,948 | $635,591 | −$333,892 | $158,876 | $536,302 |
| Other non-cash items | $438.47B | $88 | $123 | $135 | $135 | $124,765 | $154 | $229 | $179,066 | $131 | $147 | $159 |
| Cash from operating activities | −$2.1M | −$1.9M | −$2.0M | −$1.6M | −$1.7M | −$2.0M | −$2.2M | −$2.6M | −$1.5M | −$1.9M | −$1.7M | −$1.2M |
| Investing activities | ||||||||||||
| Capital expenditures | −$84.32B | −$2 | −$1 | −$84,315 | −$10,200 | −$5 | −$5 | −$46,764 | −$98,163 | −$44,632 | −$5,474 | −$8,291 |
| Investments (net) | — | — | — | −$84,317 | −$10,200 | $0 | $0 | −$46,764 | −$98,163 | −$44,632 | −$5,474 | −$8,291 |
| Acquisitions & other investing | $252.95B | −$84.32B | $2 | $84,315 | $10,200 | — | — | $46,764 | $98,163 | $44,632 | $5,474 | $8,291 |
| Cash from investing activities | $168.63B | −$84.32B | $1 | −$84,317 | −$10,200 | — | — | −$46,764 | −$98,163 | −$44,632 | −$5,474 | −$8,291 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $6.1M | $1.2M | $728,080 | $575,503 | $2.3M | $1.7M | $0 | $0 | $0 | $0 |
| Other financing | $1.7M | −$6,742 | $0 | $0 | $0 | $0 | $0 | $0 | $3.1M | $0 | $0 | $0 |
| Cash from financing activities | $1.7M | −$6,742 | $6.1M | $1.2M | $728,080 | $575,503 | $2.3M | $1.7M | $3.1M | $0 | $0 | $0 |
| Summary | ||||||||||||
| Net change in cash | −$419,146 | −$1.9M | $4.0M | −$432,853 | −$984,026 | −$1.4M | $91,763 | −$931,489 | $1.5M | −$2.0M | −$1.7M | −$1.2M |
| Cash at end of period | $2.8M | $3.2M | $5.2M | $1.1M | $1.6M | $2.5M | $4.0M | $3.9M | $4.8M | $3.3M | $5.2M | $7.0M |
| Free cash flow | $3.20T | −$1.9M | −$2.0M | −$1.7M | −$1.7M | −$2.0M | −$2.2M | −$2.6M | −$1.6M | −$2.0M | −$1.7M | −$1.2M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
NNVC cash generation
In fiscal 2026 (ended June 30, 2026), NanoViricides generated -$7.70 trillion of cash from operations and spent $84.3 billion on capital expenditures, leaving free cash flow of -$7.78 trillion. Cash and equivalents rose by $1.24 trillion over the year.
Related: NNVC income statement, NNVC balance sheet. See the NNVC stock overview for the latest quote and news.
NNVC cash flow FAQ
What is NanoViricides's free cash flow?
NanoViricides's free cash flow was -$7.78 trillion in fiscal 2026: -$7.70 trillion of operating cash flow minus $84.3 billion of capital expenditures It was -$8.5 million a year earlier..
How much cash does NanoViricides generate from operations?
NanoViricides generated -$7.70 trillion of cash from operating activities in fiscal 2026.
How much does NanoViricides spend on capital expenditures?
NanoViricides spent $84.3 billion on capital expenditures in fiscal 2026, compared with $0.1 million the year before.